Story perspectives
FDA Rejects Vanda's Drug Amid Gastroparesis Innovations
1/17/2025
48 5
1 of 1
Story summary
- The Gastroparesis landscape is buzzing with innovation, featuring over 10 companies racing to develop more than 11 therapies. However, Vanda Pharmaceuticals faced a setback when the FDA rejected its tradipitant in September 2024, citing safety and effectiveness concerns. Meanwhile, promising treatments like CIN-102 and Metoclopramide Nasal Spray are in clinical trials, potentially reshaping the future of care.
